Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Chief Medical Officer | January 02, 2025 | January 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tempest Therapeutics, Inc.
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.86 · Expires 2035-01-01 | Direct | 270,000 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 270,000 · Balance 270,000 F1: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 6, 2025 22:00 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 270,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001415889-25-000806 · form4-01062025_050114.xml · derivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 2, 2025, subject to the Reporting Person's continued service. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 23:35 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | PurchaseCommon Stock | 4,672 | $2.13 | $9,951.36 |
DisclosureSEC source: 0001415889-24-019279 · form4-07032024_110739.xml · nonDerivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,573 F1 · balance_after: Includes 3,000 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 21:40 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001209191-24-001038 · doc4.xml · derivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2024, subject to the Reporting Person's continued service. Read SEC document |
| October 11, 2023 Filed Oct 13, 2023 20:39 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 325,000 | $0.00 Strike: $9.77 | $0.00 |
DisclosureSEC source: 0001209191-23-052781 · doc4.xml · derivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2033-10-10 F1 · derivative.exercise_date: 25% of the award shall vest on October 11, 2024 and the remainder of the award shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:02 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 69,700 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002148 · doc4.xml · derivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,700 Underlying: Common Stock · 69,700 shares Expires 2033-01-02 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 20:32 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 55,680 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001179110-22-003400 · edgar.xml · derivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,680 Underlying: Common Stock · 55,680 shares Expires 2032-06-20 F1 · derivative.exercise_date: Vests over four (4) years, with one-fourth (1/4) of the award vesting on the first anniversary of the date of grant and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:37 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | PurchaseCommon Stock | 1,700 | $4.80 | $8,168.16 |
DisclosureSEC source: 0001209191-22-002753 · doc4.xml · nonDerivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,901 Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 00:25 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 29,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001209191-22-002249 · doc4.xml · derivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from January 4, 2022, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 20:16 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 540,231 | Not disclosed Strike: $26.40 | Not disclosed |
DisclosureSEC source: 0001140361-21-022931 · form4.xml · derivative · entry 4 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,231 Underlying: Common Stock · 540,231 shares Expires 2031-04-28 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F4 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of Closing, June 25, 2021, subject to the reporting person's continued service. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 20:16 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 3,018 | Not disclosed Strike: $10.25 | Not disclosed |
DisclosureSEC source: 0001140361-21-022931 · form4.xml · derivative · entry 3 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,018 Underlying: Common Stock · 3,018 shares Expires 2031-03-09 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F3 · derivative.exercise_date: These stock options vest in a series of 48 equal monthly installments measured from the vesting commencement date of March 5, 2021, subject to the reporting person's continued service. Notwithstanding the foregoing, if, within three months prior to or 12 months following a change in control, the Issuer terminates the reporting person's employment without cause or the reporting person resigns for good reasons, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares subject to the option will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 20:16 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 61,945 | Not disclosed Strike: $5.90 | Not disclosed |
DisclosureSEC source: 0001140361-21-022931 · form4.xml · derivative · entry 2 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,945 Underlying: Common Stock · 61,945 shares Expires 2030-11-15 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F2 · derivative.exercise_date: One-fourth of the shares underlying this option vest on November 16, 2021, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. Notwithstanding the foregoing, if within three months prior to or 12 months following a change in control Tempest terminates the reporting person's employment without cause or the reporting person resigns for good reason, then the vesting of all of the shares subject to this option will be immediately accelerated such that all shares will be deemed fully vested and exercisable as of the reporting person's last day of employment, provided that the reporting person satisfies certain severance conditions. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 20:16 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantCommon Stock | 201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-022931 · form4.xml · nonDerivative · entry 1 Whiting Samuel · CIK 0001870373 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), (i) each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock (the "Exchange Ratio"), and (ii) each outstanding and unexercised option to purchase shares of Tempest common stock converted into an option to purchase shares of Millendo's common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.